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Abstract Medulloblastomas (MB) are the most common
malignant brain tumors in childhood. Alkylator-based drugs
are effective agents in the treatment of patients with MB.
In several tumors, including malignant glioma, elevated
O6-methylguanine-DNA methyltransferase (MGMT) expres-
sion levels or lack of MGMT promoter methylation have
been found to be associated with resistance to alkylating
chemotherapeutic agents such as temozolomide (TMZ). In
this study, we examined the MGMT status of MB and
central nervous system primitive neuroectodermal tumor
(PNET) cells and two large sets of primary MB. In seven
MB/PNET cell lines investigated, MGMT promoter
methylation was detected only in D425 human MB cells as
assayed by the qualitative methylation-specific PCR and the
more quantitative pyrosequencing assay. In D425 human
MB cells, MGMT mRNA and protein expression was
clearly lower when compared with the MGMT expression
in the other MB/PNET cell lines. In MB/PNET cells, sen-
sitivity towards TMZ and 1-(2-chloroethyl)-3-cyclohexyl-
1-nitrosourea (CCNU) correlated with MGMT methylation
and MGMT mRNA expression. Pyrosequencing in 67 pri-
mary MB samples revealed a mean percentage of MGMT
methylation of 3.7–92% (mean: 13.25%, median: 10.67%).
Percentage of MGMT methylation and MGMT mRNA
expression as determined by quantitative RT-PCR corre-
lated inversely (n = 46; Pearson correlation r2 = 0.14,
P = 0.01). We then analyzed MGMT mRNA expression in
a second set of 47 formalin-fixed paraffin-embedded pri-
mary MB samples from clinically well-documented patients
treated within the prospective randomized multicenter trial
HIT’91. No association was found between MGMT mRNA
expression and progression-free or overall survival. There-
fore, it is not currently recommended to use MGMT mRNA
expression analysis to determine who should receive
alkylating agents and who should not.
Keywords Childhood brain tumors  Medulloblastoma 
MGMT  Methylation
Introduction
Medulloblastomas (MB) are the most common malignant
brain tumors in childhood [1]. They show biological sim-
ilarities with central nervous system supratentorial primi-
tive neuroectodermal tumors (CNS PNET). Because of the
high risk of leptomeningeal dissemination, standard
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postoperative treatment includes craniospinal radiotherapy
and chemotherapy. Over the last decade, progress has been
made in defining clinical and biological prognostic factors
that define risk groups and help direct therapy decisions for
children with MB. However, our ability to predict response
to current treatment is poor.
Alkylating agents, the oldest class of anticancer drugs,
are a heterogeneous group of drugs used in the treatment
of many cancers including MB [2–4]. Alkylators attacking
the O6 position of guanine fall into two major classes:
chloroethylating agents, such as 1-(2-chloroethyl)-3-cyclo-
hexyl-1-nitrosourea (CCNU) and 1,2-bis(2-chloroethyl)-
1-nitrosourea (BCNU), and methylating agents, such as
procarbazine and temozolomide (TMZ). At the O6 position
of guanine, induced DNA adducts are repaired by
O6-methylguanine-DNA methyltransferase (MGMT) [5].
This protein acts as a ‘‘suicide’’ acceptor protein for the
alkyl group, restoring DNA to normal but inactivating itself
in the process [6, 7]. Thus, the ability of a cell to withstand
such damage appears to be directly related to the number of
MGMT molecules it contains and to the rate of de novo
synthesis of MGMT [8]. As such, it is a unique DNA repair
protein. There are no back-up mechanisms or any redun-
dancy in the DNA repair process of O6-alkylguanine
lesions [9]. If repair of the alkylation does not occur, most
O6-chloroethylguanine lesions are converted to G–C
interstrand crosslinks within 8–12 h [10]. These are very
poorly repaired in mammalian cells, forcing a halt to the
DNA replication, formation of single- and double-strand
breaks, and induction of p53 and p21, which leads to
apoptotic and necrotic cell death [6]. O6-methylguanine
can pair with thymine during DNA replication, resulting in
conversion of guanine-cytosine to adenine–thymine pairs
in DNA [11]. However, the most likely explanation for the
cytotoxicity of O6-methylguanine lesions is that it ema-
nates from the induction of mismatch repair at O6-mG:T
sites [12]. Because mismatch repair targets the newly
synthesized strand for re-synthesis, O6-mG on the parent
strand remains and repetitive cycling of aberrant repair
takes place, which induces apoptosis in a fairly efficient
manner [6].
Several studies have suggested a favorable association
between MGMT methylation/low MGMT levels and
response to chloroethylating and methylating agents in
adults and children with malignant glioma [13–16]. In
pediatric MB, He et al. [17] demonstrated absence of
MGMT mRNA and protein expression in D425 Med and
D458 Med cell lines. Hongeng et al. [18] found higher
levels of MGMT in MB when compared with gliomas. A
single MB examined was hypermethylated at MGMT [8].
Rood et al. [19] found methylation of MGMT in 28 of
37 MB samples. However, no correlation was found
between MGMT methylation and mRNA expression.
Microarray-based screening in 35 MB revealed that high
levels of MGMT correlated with unfavorable survival out-
come [20]. Bobola et al. [21] studied MB cell lines and
found that MGMT is a major determinant of BCNU and
TMZ sensitivity.
In this study, we investigated MGMT methylation in
MB/PNET cell lines and primary MB and investigated
whether MGMT methylation reflects the expression of the
gene. We then investigated the response of MB/PNET cells
to TMZ and CCNU, and evaluated the potential prognostic
significance of MGMT expression in a relatively uniformly
treated patient population.
Materials and methods
Cell lines
DAOY human MB cells were purchased from the Ameri-
can Type Culture Collection (Rockville, MD). SW48
(colon carcinoma), D341 (MB), D425 (MB), UW228-2
(MB), Med-1 (MB), PFSK (PNET), and PNET-5 cells were
gifts from several universities and medical centers. DAOY,
D341, and D425 cells were cultured in Richter’s Zinc
Option medium/10% fetal bovine serum (FBS); (D341 and
D425 were additionally cultured with 1% nonessential
amino acids); PFSK cells were cultured in RPMI 1640/10%
FBS; and SW48, PNET-5, Med-1, and UW228-2 cells were
cultured in Dulbecco’s modified Eagle’s medium (Gibco
Invitrogen, Basel, Switzerland)/10% FBS. All cell cultures
were maintained at 37C in a humidified 5% CO2
atmosphere.
Peripheral blood lymphocytes
Peripheral blood lymphocytes (PBL) cells were separated
from the first author’s blood using Leucosep (Greiner Bio-
One, Frickenhausen, Germany) according to the manufac-
turer’s instructions.
Drugs and chemicals
Stock solutions of TMZ (Schering-Plough, Kenilworth,
NJ, USA) and O6-benzylguanine (Sigma-Aldrich, Basel,
Switzerland) were prepared in DMSO and stored at -80C.
CCNU (Lomustine; Bristol-Myers Squibb, Baar, Switzer-
land) was prepared fresh in 10% ethanol (0.05 mg per ml).
Quantitative RT-PCR
Total RNA isolation, reverse transcription reactions, and
RT-PCR were performed as described previously [22].
Kinetic real-time PCR quantification of target genes was
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performed using the ABI Prism 7700 Sequence Detection
System (Applied Biosystems, Rotkreuz, Switzerland), as
described previously [23]. Primers and probes for MGMT
(assay ID: Hs01037698_m1) and the endogenous control
18S rRNA (assay ID: Hs99999901_s1) were purchased
from Applied Biosystems. Experiments were performed in
triplicate for each data point. Relative mRNA expression of
target genes was calculated by using the comparative CT
method [24]. The amount of MGMT was normalized to
18S rRNA and calibrated to a commercially available
normal human cerebellum probe (Clontech, Saint-Germain-
en-Laye, France).
Western blot analysis
The expression of MGMT and b-actin protein was assessed
by western blot analysis. In brief, pellets of MB/PNET
cells were lysed with lysis buffer (1 ml/107 cells, 50 mM
Tris–HCl buffer pH 8.0, 150 mM NaCl, 1% Nonidet P40,
0.1% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
1 mM EDTA, and 1 mM EGTA pH 8.0) containing fresh
protease inhibitors (Complete; Roche, Basel, Switzerland)
and incubated on ice for 30 min. After estimating the pro-
tein concentration by the BCA method (Pierce, Rockford,
USA), 30 lg total protein lysates were separated by 10%
SDS polyacrylamide gels and the gels were subjected to
immunoblotting. Nonspecific binding sites were blocked
by 3 h incubation in TBST (10 mM Tris pH 8.0, 150 mM
NaCl, 0.05% Tween 20) supplemented with 5% nonfat
milk powder. Membranes were incubated overnight at 4C
with a 1:200 dilution of mouse monoclonal primary
MGMT antibody (Lab Vision, Wohlen, Switzerland).
Membranes were then washed three times at room tem-
perature in TBST for 30 min each time, and bound Ig was
detected using anti-isotype monoclonal secondary antibody
coupled to horseradish peroxidase (Santa Cruz Biotech-
nology, Heidelberg, Germany). The signal was visualized
by enhanced chemiluminescence ECL (Amersham Bio-
sciences, Du¨bendorf, Switzerland) and autoradiography.
Then immunoblotting with a 1:5,000 dilution of a mouse
monoclonal primary b-actin antibody (Sigma-Aldrich,
Buchs, Switzerland) was performed to verify equivalent
amounts of loaded protein.
DNA and RNA isolation from formalin-fixed
and paraffin-embedded tumor samples
The Recover All Total Nucleic Acid Isolation kit (Ambion,
Austin, USA) was used to isolate DNA and RNA from
archive MB samples. Briefly, 5-lm sections were cut from
10% neutral-buffered formalin-fixed (24 h), paraffin-
embedded blocks, placed in RNase-free, 1.5-ml Eppendorf
tubes and deparaffinized with xylene. The samples were
washed with ethanol, centrifuged for 5 min at 13,000g, air-
dried, and resuspended in 400 ll digestion buffer (Ambion)
containing 4 ll proteinase K (60 units/ll). Samples were
vortexed and incubated for 3 h at 50C, centrifuged at
1,400g to extract RNA and incubated for 24 h at 50C, then
centrifuged at 1,400g to extract DNA. After complete
digestion, 480 ll Isolation Additive was added and the
samples were vortexed. Then, 1.1 ml 96% ethanol was
added to each sample and mixed in carefully. The sample/
ethanol mixture was applied to a filter cartridge and cen-
trifuged for 30 s at 10,000g. After the filter cartridge was
washed and the residual fluid was removed, 60 ll of DNase
mix were added for RNA extraction or 60 ll of RNase for
DNA extraction to the center of the filter. DNase was
incubated for 30 min at room temperature and the RNase
was incubated for 30 min at 37C. The nucleic acid was
eluted with 30 ll of nuclease-free water heated to 95C.
DNA from cell lines and PBL was isolated using the QIA-
amp DNA Mini Kit (Qiagen, Switzerland) according the
manufacturer’s protocol [25].
Methylation-specific polymerase chain reaction
Methylation-specific PCR (MSP) was performed as previ-
ously described [26]. In brief, genomic DNA was bisulfite-
converted using the EZ DNA Methylation Kit (Zymo
Research, Orange, USA). The reaction transforms unme-
thylated cytosine residues into uracil but not their meth-
ylated counterpart [19]. Purified, bisulfite-treated DNA was
subjected to MSP using a two-step approach with nested
primers. The first round of PCR amplifies both the meth-
ylated and unmethylated sequence of MGMT that serves as
template in the second step in which two independent
reactions are performed amplifying either the methylated
or unmethylated MGMT sequence using methylation-spe-
cific primers. DNA from SW48 cells served as positive
control and PBL as negative control. The PCR products
were separated and visualized on a 4% agarose gel.
Pyrosequencing
The pyrosequencing experiments were performed by
EpigenDX (Worcester, USA). This pyrosequence assay
analyzed MGMT promoter methylation in eight CPG
positions (CPG8–CPG15) extending from nucleotides ?17
to ?81 relative to transcription started site (based on
Ensembl sequence: ENST00000306010) [27, 28]. A stan-
dard pyrosequencing sample preparation protocol was
applied as described previously [27, 29]. Briefly, PCR was
performed using the appropriate primers with a final vol-
ume of 50 ll. The initial denaturation (97C, 15 min) was
followed by 38 cycles of 1 min at 95C, 1 min at 47.5C,
1 min at 72C, and a final extension step at 72C for
J Neurooncol (2011) 103:59–69 61
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10 min. We subjected 40 ll of the PCR product to
pyrosequencing. The sequencing reaction was performed
on an automated PSQ 96MA System (Biotage, Uppsala,
Sweden) using the Pyro Gold reagents kit (Biotage).
Purification and subsequent processing of the biotinylated
single strand DNA was performed according to the man-
ufacturer’s instructions. Resulting data were analyzed and
quantified with the PSQ 96MA 2.1 software (Biotage).
Each sample was analyzed in triplicate by individual PCR
reactions using the same bisulfite preparation as template.
Methylation values B5% were considered as potential
background noise signals of questionable significance, in
concordance with other publications [30–32].
Cell proliferation
The appropriate number of MB cells were seeded in
96-well plates, treated the next day with various concen-
trations of TMZ or CCNU, and incubated for 5 and 4 days,
respectively, at 37C in a humidified 5% CO2 atmosphere.
The specific MGMT inhibitor, O6-benzylguanine, was added
2 h before TMZ or CCNU treatment at a concentration of
25 lM [33]. A colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium inner salt (MTS) assay (Promega, Wallisellen,
Switzerland) was used to quantitate cell viability as pre-
viously described [22, 34]. Following incubation, 10 ll of
MTS working solution was added to each culture well, and
the cultures were incubated for 3.5 h at 37C in a humid-
ified 5% CO2 atmosphere. Each experiment was performed
in triplicate. The absorbance values of each well were
measured with a microplate spectrophotometer (Molecular
Devices, Sunnyvale, CA, USA) at 490 nm. IC50 values
were calculated from the regression curve as previously
described [35]. All proliferation assays were repeated as
independent experiments at least twice.
Patients and therapy
Tumor material was available from two sets of archival MB
samples. One set contained tumor samples from patients
diagnosed in Zurich, Switzerland (n = 57) and Cairo,
Egypt (n = 10). All these samples were reviewed by two
neuropathologists (J.H., M.M.) and diagnosed as MB.
However, the clinical information (mainly metastatic stage)
for this set is incomplete and the therapy received was not
homogeneous. For the other set, tumor material was avail-
able from 47 children registered between December 1991
and October 1997 to the prospective randomized multi-
center trial HIT’91. After surgery, patients were random-
ized to receive either craniospinal radiotherapy followed by
maintenance chemotherapy (‘maintenance arm’) or neoad-
juvant chemotherapy and craniospinal radiotherapy
(‘sandwich arm’) as described [36]. Briefly, neoadjuvant
‘sandwich’ chemotherapy consisted of procarbazine fol-
lowed by two cycles of ifosfamide/etoposide, high-dose
methotrexate, and cisplatin/cytarabine; poor responders
received eight additional cycles of carboplatin/CCNU/vin-
cristine after radiotherapy. Maintenance chemotherapy
consisted of eight courses of cisplatin, CCNU, and vin-
cristine. Radiotherapy consisted of 35.2 Gy to the neuraxis,
a boost of 20 Gy to the posterior fossa, and an additional
boost to macroscopic metastases if present.
Statistical analysis
All data are expressed as mean ± SD. GraphPad Prism 4
(GraphPad Software, San Diego, CA, USA) software was
used to calculate IC50 values and to determine correlations
between IC50 values of TMZ or CCNU and MGMT
mRNA expression. Survival functions were estimated
using the method of Kaplan and Meier, and the log-rank
test was used for comparison. Progression-free survival
(PFS) was defined as time from the date of diagnosis to the
date of first progression, relapse, or death from any cause,
or to the date of the last contact. Overall survival (OS) was
defined as the time from the date of diagnosis to death from
any cause or to last contact. Standard errors are expressed
as plus-minus values. The univariable analyses were done
on a local significance level of 5% and were not adjusted
for multiple comparisons. Multivariable Cox regression
analysis was used to analyze possible confounding vari-
ables to the influence of MGMT status on the risk of
recurrence or death. The forward stepwise model selection
procedure according to Collet was used to define the final
model (P value of likelihood-ratio test B0.05 as inclusion
criteria; likelihood-ratio test C0.10 as exclusion criteria).
The following variables were entered into the analyses:
gender, age at diagnosis, histologic subtype (classic, des-
moplastic, and anaplastic medulloblastoma), stage [no
metastases, no macroscopic metastasis without cerebro-
spinal fluid (CSF) examination, microscopic without
macroscopic, and macroscopic metastases], extent of pri-
mary tumor resection (gross total resection, incomplete
resection), and treatment regimen (‘maintenance arm’,
‘sandwich arm’). Approval to perform the study was
obtained from the Institutional Review Board.
Results
MGMT status of MB/PNET cells
To measure the methylation status of MGMT promoter in
MB/PNET cells, we performed two different assays, MSP
and the more quantitative pyrosequencing assay. MSP
62 J Neurooncol (2011) 103:59–69
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demonstrated MGMT promoter methylation in one (D425)
of seven MB/PNET cell lines tested (Fig. 1a). This result
was validated by pyrosequencing. The mean percentage of
MGMT methylation in D425 cells was 81.9% compared
with 1.7–3.0% in the other six MB/PNET cell lines tested
(Fig. 1b). In D425 human MB cells where MGMT pro-
moter methylation was demonstrated, MGMT mRNA
expression as determined by RT-PCR and MGMT protein
expression as determined by western blotting were nearly
absent (Fig. 1c, d).
MB/PNET cell sensitivity to TMZ and CCNU
The cytotoxic effects of TMZ and CCNU were examined
in seven MB/PNET cell lines by using the MTS assay. The
IC50 values (averaged from two independent experiments)
for TMZ ranged from 3.9 to 340.1 lM (D425: 3.9 lM;
PFSK: 78.9 lM; DAOY: 163.5 lM; D341: 234.6 lM;
UW-228-2: 267.2 lM; Med-1: 340.1 lM; and PNET-5:
227.7 lM) (Fig. 2a). In the case of CCNU, the IC50 values
ranged from 4.1 to 100.7 lM (D425: 4.1 lM; PFSK:
27.1 lM; DAOY: 43.9 lM; D341: 31.0 lM; UW-228-2:
73.2 lM; Med-1: 100.7 lM; and PNET-5: 34.4 lM)
(Fig. 2b). To further define the role of MGMT in mediating
resistance to alkylating agents in MB/PNET, we tested
whether the MGMT inhibitor O6-benzylguanine is able to
sensitize to TMZ and CCNU [4, 7]. O6-benzylguanine
co-exposure had no effect in D425, little effect in PFSK
and D341, but shifted the IC50 in the MTS assay from
154.7 to 24.0 lM in DAOY, from 293.5 to 53.9 lM in
UW-228-2, from 315.7 to 21.5 lM in Med-1, and from 225
to 13 lM in PNET-5 (Fig. 2a). Sensitization to CCNU-
mediated cell killing by O6-benzylguanine co-exposure
was similar. We observed no effect in D425, little effect in
PFSK and D341, but O6-benzylguanine shifted the IC50 in
the MTS assay from 33 to 12.3 lM in DAOY, from 69.3
to 33.2 lM in UW-228-2, from 83 to 9.6 lM in Med-1,
and from 36.3 to 29 lM in PNET-5 (Fig. 2b).
We then compared sensitivity towards TMZ and CCNU
with mRNA expression of MGMT. IC50 values—determined
Fig. 1 Methylation status of the MGMT promoter in MB/PNET and
control cells, as determined by nested methylation-specific PCR
(a) and pyrosequencing (b). Controls included peripheral blood
lymphocytes (PBL) with unmethylated (U) MGMT promoter, SW480
colon cancer cells with methylated (M) MGMT promoter, and water.
A 100-bp marker ladder was loaded to estimate molecular size. D425
contains a methylated MGMT promoter, whereas all other MB/PNET
cells harbor only an unmethylated promoter. Pyrosequencing assay
measured level of methylation in eight CpG island of MGMT
promoter regions (x-axis). The y-axis shows the percentage of
methylation in each CpG-island. c MGMT mRNA as determined by
quantitative RT-PCR. Values represent the relative MGMT mRNA
expression compared with a normal human cerebellum sample
(n = 3; ±SD). d MGMT protein expression as determined by
western blot analysis
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Fig. 2 TMZ- (a) and CCNU-
mediated (b) cytotoxicity in
human MB/PNET cells as
determined by the MTS assay.
Experiments were performed
with (black squares)
or without (solvent only)
O6-benzylguanine pre-treatment
(25 lM; 2 h). Values represent
the mean percentage of viability
(representative from two
independent experiments;
n = 5; ±SD). c Comparison of
TMZ sensitivity and MGMT
mRNA expression in MB/PNET
cells. d Comparison of CCNU
sensitivity and MGMT mRNA
expression in MB/PNET cells
64 J Neurooncol (2011) 103:59–69
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in the acute growth inhibition assay—of TMZ and MGMT
mRNA expression levels correlated significantly (Fig. 2c;
r2 = 0.61, P = 0.037). In the case of CCNU, the correlation
was not significant (Fig. 2d; r2 = 0.33, P = 0.18).
MGMT promoter methylation and MGMT mRNA
expression in primary MB samples
We then used the pyrosequencing method to measure
MGMT promoter methylation in DNA extracted from 67
formalin-fixed, paraffin-embedded primary MB samples.
Pyrosequencing revealed a mean percentage of MGMT
methylation of 3.7–92% (mean: 13.25%, median: 10.67%)
(Fig. 3a). Quantitative RT-PCR of 46 corresponding MB
samples with sufficient tumor material to perform RT-PCR
revealed MGMT mRNA expression levels of 0.00–6.68
(mean: 1.67, median: 1.01; relative to normal cerebellum).
Mean percentage of MGMT methylation correlated inver-
sely with MGMT mRNA expression (Pearson correlation
r2 = 0.14, P = 0.01; Fig. 3b). Since the clinical informa-
tion for this set of primary MB samples was incomplete
and the therapy received not homogeneous, a survival
analysis was not performed. We then used another set of
primary MB samples to correlate MGMT status and sur-
vival outcome. For this second set, clinical information was
complete, with cDNA already available from a previous
study [37], but with no genomic DNA available to perform
MGMT methylation analysis. We therefore used quantita-
tive RT-PCR instead of pyrosequencing.
MGMT mRNA expression and survival outcome
in primary MB samples
In an attempt to ascertain whether MGMT mRNA expres-
sion predicts survival outcome probability, we analyzed
MGMT mRNA expression in formalin-fixed, paraffin-
embedded tumor samples from well-documented patients
treated within the prospective randomized multicenter trial
HIT’91. Samples from 47 patients were available for
analysis. Median age at diagnosis was 7.5 years (range,
2.9–17.0). Twenty-eight patients were male, 19 were
female. Twenty-three patients had no metastases, 3 patients
had no macroscopic metastases and no CSF examination at
diagnosis, 13 patients had microscopic CSF but no macro-
scopic metastases, and 8 patients had macroscopic central
nervous system metastases. Histologic subtype was clas-
sic in 42, desmoplastic in 3, and anaplastic in 2 patients.
Thirty-two patients had no post-operative macroscopic
primary residual tumor as assessed by early-postoperative
Fig. 3 a MGMT promoter methylation in 67 formalin-fixed paraffin-
embedded primary MB samples as determined by pyrosequencing.
b Mean percentage of MGMT promoter methylation correlates with
the MGMT mRNA expression levels as determined by quantitative
RT-PCR (n = 46)
Fig. 2 continued
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imaging; in 15 patients, primary tumor resection was
incomplete. Twenty-one patients were treated within the
‘maintenance arm’ and 26 patients within the ‘sandwich
arm’. Median follow-up time of surviving patients was
7.0 years (range, 3.8–12.0). Median MGMT mRNA
expression was 2.15 (range, 0.00–231.60; 25th and 75th
percentiles 0.00 and 10.56, respectively). Five-year PFS of
patients with MGMT expression levels lower or equal to the
median was 54.2% (±10.2%), and 60.2% (±10.4%) in
those with higher MGMT expression levels (P = 0.738)
(Fig. 4a). For 5-year OS, survival probabilities were 58.3%
(±10.1%) and 64.6% (±10.1%), respectively (P = 0.720)
(Fig. 4b). In a multivariate Cox regression analysis, MGMT
expression level was not shown to be an independent
prognostic factor for either PFS or OS.
Discussion
Resistance to cytotoxic drugs remains a significant barrier
to the successful treatment of high-risk MB patients. The
contribution of MGMT to alkylating agent resistance, as
well as the promise and limitations of O6-benzylguanine in
suppressing resistance, have been thoroughly examined in
cell lines and xenografts derived from adult and pediatric
gliomas [21, 38–41]. Also, several studies have suggested a
favorable association between low MGMT levels and
response to chloroethylating and methylating agents in
adults and children with malignant glioma [13–16]. How-
ever, for MB, the most common malignant brain tumor in
children, information about factors regulating sensitivity
towards alkylating agents is largely missing.
Several methods for measuring MGMT levels within
tumors have been described [41]. These include high-per-
formance liquid chromatography (HPLC) for measuring
enzymatic activity and immunohistochemistry for detecting
protein level. Preusser et al. [42] recently published a large
study on MGMT immunohistochemistry in 164 glioblas-
toma multiforme samples of glioblastoma. Using two dif-
ferent commercial anti-MGMT antibodies (clones MT3.1
and MT23.2), they found major observer variability and no
significant association of MGMT protein expression with
the MGMT promoter methylation status and patient sur-
vival. We therefore decided not to perform MGMT immuno-
histochemistry. Loss of MGMT expression is commonly
due to MGMT promoter methylation [8, 13]. Epigenetic
silencing of the MGMT gene by promoter methylation can
be assessed using MSP [43]. One advantage of the MSP
assay lies in the fact that detection of the methylated MGMT
allele can be attributed solely to neoplastic cells [44].
Therefore, nontumor tissue contamination of the surgical
specimen does not interfere with the result [41]. In this
study, we used MSP and the more quantitative pyrose-
quencing technique [45] to measure MGMT methylation in
MB. As shown in the tumor cells analyzed, the results of
these two different methods correspond well. In human
D425 MB cells, promoter methylation shuts down MGMT
gene expression. This finding is in agreement with an earlier
report showing absence of MGMT expression in D425 as
determined by northern and western blot analysis [17]. In
the other six human MB/PNET cell lines tested, mean
percentage of methylation as determined by pyrosequenc-
ing was only 1.7–3.0%. Clearly, characteristics of cells can
change when cultured for extended periods. Therefore,
additional studies including primary cell cultures are nee-
ded to validate these findings.
Fig. 4 PFS and OS in a cohort of uniformly treated patients with MB
(n = 47) according to relative MGMT mRNA expression levels in
primary tumor tissue
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Our in vitro findings analyzing a panel of seven human
MB/PNET cell lines indicate that MGMT methylation
and/or mRNA expression may predict response to the
alkylating agents CCNU and TMZ. However, since only
one MB/PNET cell line was MGMT methylated, extended
studies are needed for validation. CCNU has been widely
used in MB for more than two decades, whereas TMZ only
started to be incorporated in first and second line protocols
later [46, 47]. The IC50 values found for CCNU (range,
4.1–100.7 lM) and TMZ (range, 3.9–340.1 lM) corre-
spond well with the values reported for other brain tumor
cells [48–51]. Further evidence about the important role of
MGMT in determining resistance in MB/PNET tumor cells
was provided by our analysis of cell viability after treat-
ment with TMZ or CCNU in combination with the specific
MGMT inhibitor O6-benzylguanine. D425, with absent
MGMT expression, showed high sensitivity to TMZ and
CCNU treatment. PFSK cells express low levels of
MGMT, and O6-benzylguanine-mediated sensitization to
TMZ and CCNU was modest. O6-benzylguanine strongly
sensitized Med-1 and PNET-5 cells, characterized by high
MGMT expression levels, to TMZ and CCNU, indicating
that MGMT is a predictor of sensitivity in MB/PNET
tumor cells. On the other hand, the fact that not all cells
respond similarly to O6-benzylguanine co-treatment sug-
gest that additional factors, including MMR proteins
[49], p53 [52] and apoptotic proteins, might play also a role
in MB/PNET.
We then used pyrosequencing to measure MGMT pro-
moter methylation in DNA isolated from 67 formalin-fixed,
paraffin-embedded primary MB samples and found a wide
range of MGMT methylation (3.7–92%, mean: 13.25%,
median: 10.67%). MGMT methylation correlated inversely
with MGMT mRNA expression. We therefore tested in a
second set of primary MB, where cDNA was already
available from a previous study [37], the hypothesis whe-
ther MGMT mRNA expression correlates with progres-
sion-free and/or survival outcome, but this was not the
case. Clearly, this result needs to be interpreted cautiously,
since the multimodal therapy of these patients included not
only alkylating agents but also other cytotoxic drugs and
radiotherapy.
Since MGMT is not (methylation values B5%) or only
mildly (B10%) methylated in a subgroup of MB, methods
of inhibiting or depleting MGMT need to be discussed.
O6-benzylguanine is a potent MGMT-inactivating agent
that has been studied in combination with alkylating agents.
It inactivates MGMT stoichiometrically [7]. However,
O6-benzylguanine lowers MGMT levels in normal cells as
well, increasing toxicity from chemotherapy [41]. Inter-
estingly, alkylating agents themselves are also MGMT-
depleting agents because of their capacity to induce DNA
damage [41]. MGMT depletion in the tumor could
potentially be achieved with alternative dosing schedules of
TMZ that deliver more prolonged exposure and higher
cumulative doses than the standard 5-day regimen (150–200
mg/m2/days for 5 days every 28-day cycle) [41, 53]. Both
compressed and extended TMZ schedules have been tested
preclinically and clinically. Early results suggest that con-
tinuous daily administration is more effective than a single
dose [54], and more frequent administration (i.e. twice daily
or every 4 h) yields the most effective depletion of MGMT
activity [55, 56]. However, normal hematopoietic cells can
also become sensitized. Profound lymphopenia has been
reported in patients receiving extended daily treatment with
TMZ at a dose of 75 mg/m2, which can lead to opportunistic
infections such as Pneumocystis jirovecii pneumonia [57, 58].
In summary, we found a weak, but statistically signifi-
cant, correlation between MGMT methylation and expres-
sion in primary MB, precluding prediction of individual
cases. Since differences in MGMT mRNA expression have
not been shown to determine the clinical course in patients
with MB, it is not recommended to use MGMT mRNA
expression analysis to determine who should receive TMZ
and/or other alkylating agents and who should not. A
promising strategy to overcome MGMT-mediated chemo-
resistance seems to be depletion of MGMT by prolonged
exposure to low doses of alkylating agents. Optimizing this
approach in conjunction with modulation of dosing
schedules seems a promising strategy to be tested in pro-
spective clinical trials in order to maximize the clinical
effectiveness of TMZ and other alkylating agents.
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